4D Molecular Therapeutics (NASDAQ:FDMT) Earns Buy Rating from Jefferies Financial Group

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “buy” rating reaffirmed by investment analysts at Jefferies Financial Group in a report released on Monday,Benzinga reports. They currently have a $21.00 target price on the stock, down from their prior target price of $40.00. Jefferies Financial Group’s price target indicates a potential upside of 127.15% from the stock’s previous close.

Several other brokerages have also recently issued reports on FDMT. Chardan Capital restated a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, March 20th. Barclays began coverage on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Finally, Wall Street Zen raised 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.25.

4D Molecular Therapeutics Trading Down 0.9%

Shares of NASDAQ FDMT traded down $0.09 during midday trading on Monday, reaching $9.25. The company had a trading volume of 240,565 shares, compared to its average volume of 773,386. 4D Molecular Therapeutics has a 1 year low of $2.23 and a 1 year high of $12.34. The business’s 50-day simple moving average is $8.93 and its 200 day simple moving average is $9.23. The stock has a market cap of $471.97 million, a P/E ratio of -3.82 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative return on equity of 31.75% and a negative net margin of 164.43%.The firm had revenue of $85.09 million for the quarter, compared to the consensus estimate of $30.86 million. Analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd purchased a new position in 4D Molecular Therapeutics during the first quarter worth approximately $39,000. Wexford Capital LP purchased a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $41,000. Quadrature Capital Ltd acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth approximately $42,000. Farther Finance Advisors LLC raised its stake in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after buying an additional 2,674 shares during the period. Finally, AQR Capital Management LLC purchased a new position in shares of 4D Molecular Therapeutics during the 1st quarter valued at approximately $46,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.